Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced today that it has received the CE Mark for the Xenoscope systems. The Xenoscope is the first single-use laparoscope that is offered in a sterile condition. It is indicated for use in diagnostic and therapeutic procedures for endoscopy and endoscopic surgery within the thoracic and peritoneal cavities including the female reproductive organs.
In comparison to present laparoscopy systems, this next generation single-use device is designed to significantly improve ease of use while providing high definition visualization of the anatomy. Other differentiating features of the Xenoscopes are the elimination of the need for cleaning and disinfection of the scope between cases and for costly service contracts.
“We are committed to advancing the state-of-the-art and providing exceptional value to clinicians and hospitals alike by bringing effective diagnostic laparoscopy modalities to world-wide markets,” said Ashok C. Khandkar, Ph.D., Chief Executive Officer of Xenocor. “This clearance allows us to bring products to world-wide markets with superior imaging characteristics including new design characteristics such as pre-white balanced illumination designed to eliminate the need for intra-operative adjustments while reducing the cost of care.”
“The Xenoscope is at the forefront of medical technologies. It provides the type of high-quality, low cost technology solutions we need to offer high value, affordable care in the United States and worldwide,” Chief Medical Officer and Internal Medicine at University of Utah Hospital. “Xenocor’s value proposition is a decade ahead of others in the field in offering safer and more cost effective healthcare.”
The Xenoscope system will be available to select centers globally, accelerating as physicians and centers gain familiarity its advantages.